Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968984 | 0.91 | EGFR (0.37) | EGFRTAAR1KDM4ENSD2ALDH1A1 | |
| SCHEMBL21411441 | 0.88 | IRAK4 (0.38) | IRAK4IRAK1KCNH2EGFRTAAR1 | |
| SCHEMBL17678348 | 0.83 | IRAK4 (0.39) | IRAK4IRAK1KCNH2KDM4ENSD2 | |
| SCHEMBL5861309 | 0.82 | KDM4E (0.57) | IRAK4IRAK1KCNH2EGFRKDM4E | |
| SCHEMBL26024454 | 0.80 | TLR8 (0.41) | KDM4ENSD2ALDH1A1MAPTBACE1 | |
| SCHEMBL21026068 | 0.79 | IRAK4 (0.41) | IRAK4IRAK1KCNH2KDM4ENSD2 | |
| SCHEMBL25153641 | 0.79 | NOTUM (0.41) | KDM4ENSD2ALDH1A1MAPTBACE1 | |
| SCHEMBL28265957 | 0.78 | HTR2A (0.44) | IRAK4IRAK1KCNH2ALDH1A1CNR2 | |
| SCHEMBL30622509 | 0.77 | KDM5A (0.46) | IRAK4IRAK1KCNH2ALDH1A1CYP1A2 | |
| SCHEMBL5860929 | 0.76 | MAPT (0.62) | IRAK4IRAK1KCNH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | IRAK4 3515/4885IRAK1 2590/4885KCNH2 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.